NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Helen TorleyCEO;Pres2026-08-197,200$106.36
$765.78kSell
Helen TorleyCEO;Pres2026-08-199,600$107.22
$1.03MSell
Helen TorleyCEO;Pres2026-08-193,200$107.77
$344.85kSell
Helen TorleyCEO;Pres2026-08-1920,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-08-185,703$103.08
$587.88kSell
Helen TorleyCEO;Pres2026-08-184,897$104.11
$509.83kSell
Helen TorleyCEO;Pres2026-08-1820,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-08-189,400$104.87
$985.82kSell
Helen TorleyCEO;Pres2026-08-1720,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-08-17900$98.96
$89.06kSell

1 of 15

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk23.47%26,633,924$2.85BInsider
Gregory Ian Frost3.21%3,641,380$389.63MInsider
Helen Torley0.68%767,780$82.15MInsider
Jonathan E. Lim0.63%710,000$75.97MInsider
John Stuart Patton0.36%412,706$44.16MInsider
Kathryn E. Falberg0.32%358,253$38.33MInsider
Robert Engler0.24%273,176$29.23MInsider
Connie Matsui0.16%183,035$19.58MInsider
Kenneth J. Kelley0.16%179,833$19.24MInsider
Michael J. Labarre0.15%173,756$18.59MInsider

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO0.11%30.26%Net SellingNet Selling
CORT0.04%99.96%Net BuyingNet Selling
MDGL0.04%99.96%Net SellingNet Selling
ARWR0.08%9.73%Net SellingNet Selling
BMRN0.10%1.80%Net SellingNet Selling

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 0.11% institutional shareholders, 30.26% Halozyme Therapeutics insiders, and 69.63% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 23.47% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $2.86B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.